Pharmaceuticals

SHANGHAI KAIBAO

SHANGHAI KAIBAO released FY2025 Annual Earnings on April 27 After-Market BJT, actual revenue CNY 1.153 B, actual EPS CNY 0.2663

SHANGHAI KAIBAO released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 283.25 M, actual EPS CNY 0.062

SHANGHAI KAIBAO released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 333.63 M, actual EPS CNY 0.0874

SHANGHAI KAIBAO to Release FY2025 Earnings on April 28 After-Market (BJT)

SHANGHAI KAIBAO to Release FY2026 Q1 Earnings on April 28 After-Market BJT

SHANGHAI KAIBAO released FY2025 9 Months Earnings on October 28 During-Market (BJT), with actual revenue of CNY 819.03 M and EPS of CNY 0.1788

SHANGHAI KAIBAO released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 214.37 M, actual EPS CNY 0.0621

SHANGHAI KAIBAO to Release FY2025 Q3 Earnings on October 29 During-Market BJT

SHANGHAI KAIBAO released FY2025 Semi-Annual earnings on August 27 After-Market (BJT), actual revenue CNY 604.66 M, actual EPS CNY 0.1166

Shanghai Kaibao released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 204.02 M, actual EPS CNY 0.036

SHANGHAI KAIBAO to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Major Shareholder of Shanghai Kaibao Plans to Reduce Shareholding by 10.46 Million Shares

Shanghai Kaibao’s Phlegm Heat Clearing Capsules Receive New Registration for COVID-19

Shanghai Kaibao Releases 2024 Annual Report

Shanghai Kaibao's Q1 2025 Net Profit Declines

SHANGHAI KAIBAO released FY2025 Q1 earnings on April 15 After-Market BJT, actual revenue CNY 400.64 M, actual EPS CNY 0.0806

SHANGHAI KAIBAO released FY2024 Q4 earnings on April 15 After-Market (BJT), actual revenue CNY 352.08 M, actual EPS CNY 0.1516

SHANGHAI KAIBAO released FY2024 annual earnings on April 15 After-Market (BJT), actual revenue CNY 1.473 B, actual EPS CNY 0.3591

Shanghai Kaibao FY2025 Q1 Earnings Release Scheduled for April 16 After-Market BJT

Shanghai Kaibao FY2024 Annual Earnings Release on April 16, 2025 After-Market BJT

300039

SHANGHAI KAIBAO announced that its revenue for the third quarter was 214 million yuan, a decrease of 26.61%; net profit was 65.0877 million yuan, a decrease of 13.13%. Revenue for the first three quarters was 819 million yuan, a decrease of 26.95%; net profit was 187 million yuan, a decrease of 13.83%

Zhitong

SHANGHAI KAIBAO: Net profit for the third quarter was 65.0877 million yuan, a decrease of 13.13%

According to the Zhitong Finance APP, SHANGHAI KAIBAO released its semi-annual report for 2025, showing an operating income of 605 million yuan, a year-on-year decrease of 27.08%. The net profit attributable to shareholders of the listed company was 122 million yuan, a year-on-year decrease of 14.20%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 117 million yuan, a year-on-year decrease of 17.81%. The basic earnings per share were 0.1166 yuan

SHANGHAI KAIBAO released its performance for the first half of the year, with a net profit attributable to the parent company of 122 million yuan, a decrease of 14.20%

688091

According to the announcement from SHANGHAI KAIBAO, the company plans to sell its shares in SHANGHAI YIZHONG through centralized bidding, block trading, or inquiry transfer based on market conditions, with the number not exceeding 6.2011 million shares

SHANGHAI YIZHONG

SHANGHAI KAIBAO plans to sell no more than 6.2011 million shares of SHANGHAI YIZHONG at an opportune time

SHANGHAI KAIBAO announced that its controlling shareholder's concerted actor, Kaiyi Trading, plans to reduce its holdings by no more than 10.46 million shares between July 23, 2025, and October 22, 2025, with a reduction ratio not exceeding 1%

The concerted action party of the actual controller of SHANGHAI KAIBAO, Kaiyi Trading, plans to reduce its holdings by no more than 1%

SHANGHAI KAIBAO recently obtained the "Drug Registration Certificate" for Phlegm-Heat Clearing Capsules issued by the National Medical Products Administration. This drug is an exclusive product of the company, mainly used for clearing heat, resolving phlegm, and detoxifying. Indications include symptoms such as mild fever, cough, and sore throat caused by wind-heat lung disease and novel coronavirus infection

SHANGHAI KAIBAO has obtained the drug registration certificate for Phlegm-Heat Clearing Capsules

According to the Qichacha APP, recently, Shanghai Fengqi Lingyan Technology Co., Ltd. was established, with Xu Shan as the legal representative and a registered capital of 10 million yuan. The business scope includes: research and development of Internet of Things technology; Internet of Things application services; software development; remote health management services; health consulting services; biomedical engineering technology services, etc. Qichacha's equity penetration shows that the company is jointly held by Nanjing Ningqi Pharmaceutical Technology Co., Ltd. and Shanghai Kaibao's Shanghai Kaibao Equity Investment Co., Ltd

SHANGHAI KAIBAO and others invest to establish a technology company, including Internet of Things-related businesses

SHANGHAI KAIBAO released its 2024 annual report, with operating revenue of 1.473 billion yuan, a year-on-year decrease of 7.57%; net profit attributable to shareholders of the parent company was 376 million yuan, a year-on-year increase of 14.55%; net profit excluding non-recurring gains and losses was 353 million yuan, a year-on-year increase of 21.16%. The basic earnings per share were 0.3591 yuan, and it is proposed to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders

SHANGHAI KAIBAO released its 2024 annual performance, with a net profit attributable to the parent company of 376 million yuan, an increase of 14.55%

SHANGHAI KAIBAO released its Q1 2025 performance report, with operating revenue of 401 million yuan, a year-on-year decrease of 15.74%; net profit attributable to shareholders of 84.2928 million yuan, a year-on-year decline of 4.71%; net profit after deducting non-recurring gains and losses of 81.8221 million yuan, a year-on-year decrease of 6.32%; basic earnings per share of 0.0806 yuan

SHANGHAI KAIBAO released its first-quarter performance, with a net profit attributable to the parent company of 84.2928 million yuan, a decrease of 4.71%

According to the Zhitong Finance APP, SHANGHAI KAIBAO announced that its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the Drug Registration Certificate for Doxofylline Tablets issued by the National Medical Products Administration. Doxofylline Tablets are suitable for bronchial asthma, asthmatic chronic bronchitis, and other respiratory difficulties caused by bronchospasm

SHANGHAI KAIBAO's wholly-owned subsidiary has obtained a drug registration certificate

According to the Qichacha APP, recently, Hainan Kaijiaoqun Medical Technology Co., Ltd. was established, with Zhang Xiaoli as the legal representative and a registered capital of 1 million yuan. The business scope includes: production of Class II medical devices; production of Class III medical devices; operation of Class III medical devices, etc. Qichacha's equity penetration shows that the company is wholly owned by Shanghai KaiBao's subsidiary, Shanghai KaiheJiao Medical Technology Co., Ltd

SHANGHAI KAIBAO(300039.SZ)